Aprea Therapeutics (APRE) Change in Account Payables (2018 - 2026)
Aprea Therapeutics (APRE) posted quarterly Change in Account Payables of $32525.0 for Q1 2026, up 145.21% year-over-year from $13263.9 in Q1 2025, and down 52.81% quarter-over-quarter from $68924.0 in Q4 2025.
Aprea Therapeutics (APRE) Change in Account Payables (2018 - 2026) Analysis & Trends
Aprea Therapeutics (APRE) has reported Change in Account Payables for 9 consecutive years, with $32525.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 145.21% year-over-year to $32525.0; the TTM figure through Mar 2026 stood at -$542241.0 (down 1411.01% YoY), while the FY2025 annual figure was -$646701.0, down 105.82% from the prior year.
- Change in Account Payables declined to $32525.0 in Q1 2026 per APRE's latest filing, from $68924.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $2.1 million in Q2 2022 and bottomed at -$2.9 million in Q3 2022.
- Historically, Change in Account Payables has averaged -$56437.2 across 5 years, with a median of -$16727.0 in 2023.
- Annual changes were most pronounced in 2023 — Change in Account Payables surged 374.65% — and 2024, when it slumped 1993.96%.
- Aprea Therapeutics' Change in Account Payables stood at -$293310.0 in 2022, then soared by 374.65% to $805590.0 in 2023, then plunged by 74.96% to $201757.0 in 2024, then tumbled by 65.84% to $68924.0 in 2025, then plunged by 52.81% to $32525.0 in 2026.
- Business Quant data shows APRE's Change in Account Payables at $32525.0 in Q1 2026, $68924.0 in Q4 2025, and -$554020.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aprea Therapeutics | 34.25 Mn | 34.25 Mn | - | 189,800.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 189,800.00 |
| Jun 30, 2026 | 189,800.00 |
| Mar 31, 2026 | 32,525.00 |
| Mar 31, 2026 | 32,525.00 |
| Dec 31, 2025 | 68,924.00 |
| Dec 31, 2025 | 68,924.00 |
| Sep 30, 2025 | -554,020.00 |
| Sep 30, 2025 | -554,020.00 |
| Jun 30, 2025 | -89,670.00 |
| Jun 30, 2025 | -89,670.00 |
| Mar 31, 2025 | -71,935.00 |
| Mar 31, 2025 | -71,935.00 |
| Dec 31, 2024 | 201,757.00 |
| Dec 31, 2024 | 201,757.00 |
| Sep 30, 2024 | 187,509.00 |
| Sep 30, 2024 | 187,509.00 |
| Jun 30, 2024 | -353,217.00 |
| Jun 30, 2024 | -353,217.00 |
| Mar 31, 2024 | -350,256.00 |
| Mar 31, 2024 | -350,256.00 |